Liver Disease Biomarkers

Liver disease is increasing globally. In addition to being an insidious condition, there are few tools to evaluate the severity of the disease besides liver biopsy (which is a highly invasive test), neither is it easy to monitor the impact of current treatments.

Liver Disease

Image Credit: Explode/

What is a biomarker?

According to the National Institute of Health (NIH), a biomarker is “a characteristic that can be objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.”  

Biomarkers help to screen for, evaluate, monitor and forecast the prognosis of specific conditions.

Specific liver biomarkers are difficult to find due to the common pathways of liver injury.

Non-alcoholic fatty liver disease (NAFLD) and its consequences

NAFLD is a term that covers a spectrum of diseases, ranging from pure steatosis, through steatosis with mild liver inflammation, to early non-alcoholic steatohepatitis (NASH), fibrotic NASH, NASH-cirrhosis and, finally, hepatocellular carcinoma (HCC). At present, a liver biopsy is a gold standard to diagnose NASH.

NAFLD biomarkers may be classified as:

  • Imaging biomarkers
  • Molecular and biochemical biomarkers
  • Novel biomarkers in the form of extracellular vesicles (EVs) and microRNAs (miRNAs)

Imaging biomarkers include

  1. Ultrasound scan – a simple, available, inexpensive method to screen for the condition, but operator-dependent and less reliable in obesity;
  2. Computed tomography scan – widely available, can assess the whole liver but involves radiation, is insensitive for mild steatosis, and is expensive;
  3. Magnetic resonance spectroscopy (MRS) – a highly reproducible technique with excellent accuracy, but is costly and time-consuming, requires operator expertise and has restricted availability;
  4. Magnetic resonance imaging proton density fat fraction (MRI-PDFF) – superior to MRS, very accurate, sensitive and offers complete liver assessment, but not freely available and very expensive;
  5. Proton-MRS – allows quantitative estimation of liver fat, but is expensive and used for research only.

Molecular and biochemical biomarkers

Serum biomarkers and disease scores are used to diagnose the presence of hepatic steatosis where imaging is unavailable or not feasible, such as in large epidemiological studies. The characteristics of a useful biomarker include:

  • Specific for the disease and the outcome
  • Safe, convenient and inexpensive
  • Must correlate with disease activity scores
  • Generalizable

The liver aminotransferases

Serum aminotransferases include aspartate and alanine aminotransferase (AST and ALT respectively), two liver enzymes that escape into the circulation upon liver damage. AST is also made in the heart and skeletal muscles and increases with strenuous exercise. It is induced by many drugs as well.

High ALT levels are therefore more specific for liver injury. However, ALT is normal in up to 80% of NAFLD patients. An ALT threshold value of 23 IU/L could pick up as many as 94% of NAFLD cases.

In the NAFLD spectrum, the AST/ALT ratio is below 1 in all diseases but advanced fibrosis.

The AST/ALT ratio also helps diagnose obstruction of the biliary tract, along with high levels of ALP (alkaline phosphatase), GGT (gamma-glutamyl transpeptidase) and bilirubin. A ratio of less than 1.5 suggests extrahepatic obstruction, while if AST/ALT is more than 1.5 the obstruction might be intrahepatic.

Again, the AST/ALT is above 1 in the 92% of alcoholic liver disease due to severe inflammation and underlying liver disease, and above 2 in the 70%.

Other biomarkers

The liver function test (LFT) consists of blood tests that measure a range of substances made by the liver, often in a single blood sample. Besides aminotransferases, this may include:

  • Albumin (the major protein in the blood) made by the liver
  • Total protein - the total amount of protein in the blood
  • ALP–a widespread enzyme family, released from the cells lining the bile ducts and canaliculi, it is raised in cholestasis, but also bone disease and kidney disease. In drug-induced cholestasis, ALP is higher than GGT, with an ALT/ALP ratio above 2. Normal aminotransferases with high ALP may indicate primary biliary cirrhosis
  • GGT is another enzyme produced by the liver microsomes, but also the kidney, pancreas, and intestine. High ALP and GGT levels indicate cholestasis. GGT also rises with alcohol and medication intake due to enzyme induction.
  • Bilirubin is a waste product formed in the liver from hemoglobin
  • Lactate dehydrogenase (LDH) which is found in multiple tissues
  • Prothrombin time (PT), a liver protein that takes part in blood clotting

Novel biomarkers

These include extracellular vesicles (EVs) and miRNAs. EV production and clearance are imbalanced in liver disease for various reasons, like overproduction from inflamed or dying cells, and reduced macrophage phagocytosis. High plasma EVs indicate progressive NAFLD, while EV content helps differentiate various etiologies.

MicroRNAs (miRNAs) are small, non-protein coding molecules that bind to mRNA and modulate many different biological functions like apoptosis, cell proliferation, and differentiation. They play an important role in chronic liver disease. NAFLD markers include miR-122, miR-34a, and its target SIRT1, and miR-29.

Liver panels in NAFLD

As of now, no non-invasive tests are approved for NASH diagnosis. Researchers have developed various ratios and indices to move towards a non-invasive diagnosis of NAFLD and fibrosis:

  • AST/platelet ratio (APRI) for advanced fibrosis and cirrhosis
  • FIB-4 score, with age, AST, ALT and platelet count for fibrosis in HIV/HCV coinfection
  • FibroIndex using platelet count, AST and gamma globulin
  • FibroTest using 6 parameters (total bilirubin, GGT, alpha-2 macroglobulin, haptoglobin, ALT, and apolipoprotein-A1) can accurately detect NASH
  • Forms index using age, platelet count, serum cholesterol and GGT for distinguishing mild and advanced fibrosis
  • PGA Index using PT, GGT, apolipoprotein A, and alpha-2 macroglobulin
  • SteatoTest that tests 12 parameters
  • NASH diagnostic panels such as the Shimada index, cytokeratin-18, and the NASH diagnostic panel, that reflect liver inflammation

Several diagnostic algorithms have been developed for the diagnosis of hepatic fibrosis in chronic hepatitis C:

  • SAFE (sequential algorithm for fibrosis evaluation) uses APRI initially, followed by FibroTest as a second-line test, and finally, a liver biopsy in up to 30%–50% of cases. This is not only inconvenient, requiring successive testing, but often invasive for the diagnosis of significant fibrosis and cirrhosis
  • The Bordeaux algorithm (BA), based on a blood test and transient elastography for liver stiffness, for significant fibrosis or cirrhosis
  • Another recent algorithm uses transient elastography with a 5-parameter (platelets, PT, AST, alpha-2-macroglobulin, GGT) blood test, with 87% sensitivity for the non-invasive diagnosis of liver fibrosis while offering 6 diagnostic classes.

Other proposed biomarkers include aPA/1 for NASH, adiponectin, IGFII, and tPA/1 for mild to moderate steatosis and MCP-1 for lobular inflammation.

New non-invasive diagnostic panels are awaited to replace liver biopsy in this field.


Further Reading

Last Updated: Mar 12, 2020

Dr. Liji Thomas

Written by

Dr. Liji Thomas

Dr. Liji Thomas is an OB-GYN, who graduated from the Government Medical College, University of Calicut, Kerala, in 2001. Liji practiced as a full-time consultant in obstetrics/gynecology in a private hospital for a few years following her graduation. She has counseled hundreds of patients facing issues from pregnancy-related problems and infertility, and has been in charge of over 2,000 deliveries, striving always to achieve a normal delivery rather than operative.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thomas, Liji. (2020, March 12). Liver Disease Biomarkers. AZoLifeSciences. Retrieved on April 18, 2024 from

  • MLA

    Thomas, Liji. "Liver Disease Biomarkers". AZoLifeSciences. 18 April 2024. <>.

  • Chicago

    Thomas, Liji. "Liver Disease Biomarkers". AZoLifeSciences. (accessed April 18, 2024).

  • Harvard

    Thomas, Liji. 2020. Liver Disease Biomarkers. AZoLifeSciences, viewed 18 April 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.